Cargando…

P932: ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY

Detalles Bibliográficos
Autores principales:	Mina, R., Bonello, F., Fazio, F., Saccardi, R., Bongarzoni, V., Marchesi, F., Bertuglia, G., Curci, P., Lemoli, R. M., Ballanti, S., Dentamaro, T., Benevolo, G., Capra, A., Floris, R., Tosi, P., Olivieri, A., Rota-Scalabrini, D., Cangialosi, C., Cavo, M., Corradini, P., Milone, G., Boccadoro, M., Larocca, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430515/ http://dx.doi.org/10.1097/01.HS9.0000846596.07227.f0

Ejemplares similares

Plerixafor
por: Slater, Susan
Publicado: (2012)

P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL
por: Larocca, A., et al.
Publicado: (2023)

Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis
por: Lazzaro, Carlo, et al.
Publicado: (2021)

P1343: TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR
por: Gunes, A. K., et al.
Publicado: (2022)

SUN-932 Successful Response of Temozolomide (TMZ) in two Patients with Metastatic Pheochromocytoma/Paragangliomas (PPGLs)
por: de Almeida, Tobias Skrebsky, et al.
Publicado: (2020)

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
por: Mina, Roberto, et al.
Publicado: (2020)

High-resolution beamline 9.3.2 in the energy range 30-1500 eV at the Advanced Light Source: design and performance
por: Hussain, Z, et al.
Publicado: (1995)

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
por: Uy, G L, et al.
Publicado: (2017)

A global checklist of the 932 fruit fly species in the tribe Dacini (Diptera, Tephritidae)
por: Doorenweerd, Camiel, et al.
Publicado: (2018)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

High resolution soft X-ray bending magnet beamline 9.3.2 with circularly polarized radiation capability at the Advanced Light Source
por: Hussain, Z, et al.
Publicado: (1995)

932. Universal Hepatitis C Virus Screening in a Tennessee Tertiary Care Emergency Department
por: Chastain, Cody A, et al.
Publicado: (2018)

932. Creating a Statewide HCV Treatment Cascade for HIV/HCV Co-Infected Persons Using a Partnership with DPH
por: Wegener, Maximilian D, et al.
Publicado: (2020)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

RB1 gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable database
por: Valverde, José R, et al.
Publicado: (2005)

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
por: Karpova, D, et al.
Publicado: (2013)

P932: PATIENT PERSPECTIVES ON BCMA-TARGETED THERAPIES FOR MULTIPLE MYELOMA: A SURVEY CONDUCTED IN A PATIENT ADVOCACY GROUP
por: Hydren, Jay R., et al.
Publicado: (2023)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Addition of plerixafor in poorly mobilized allogeneic stem cell donors
por: Zhuang, Lefan, et al.
Publicado: (2022)

Fine mapping of the major anthracnose resistance QTL AnR(GO)5 in Capsicum chinense ‘PBC932’
por: Zhao, Yuanyuan, et al.
Publicado: (2020)

Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost
por: Milone, Giuseppe, et al.
Publicado: (2020)

Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor
por: Uchida, Naoya, et al.
Publicado: (2020)

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
por: Bringhen, Sara, et al.
Publicado: (2019)

Case Study in Refractory Non-Hodgkin's Lymphoma: Successful Treatment with Plerixafor
por: Azim, Hamdy Abdel, et al.
Publicado: (2011)

Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran
por: Mehdizadeh, Mahshid, et al.
Publicado: (2013)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Use of Plerixafor to Mobilize a Healthy Donor Infected with Influenza A
por: Yeral, Mahmut, et al.
Publicado: (2018)

Whole-Genome Sequence of Escherichia coli Serotype O157:H7 Strain EDL932 (ATCC 43894)
por: Uhlich, Gaylen A., et al.
Publicado: (2016)

Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients
por: Bonello, Francesca, et al.
Publicado: (2020)

Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients
por: Clark, R E, et al.
Publicado: (2014)

A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome
por: McDermott, David H., et al.
Publicado: (2023)

P2 3-year observation study of Plerixafor use in New Zealand
por: Swinn, Tim, et al.
Publicado: (2021)

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study
por: Goto, Hiroaki, et al.
Publicado: (2022)

Development and validation of a predictive model to guide the use of plerixafor in pediatric population
por: Sebastien, Bernard, et al.
Publicado: (2022)

Choline Kinase α Inhibitors MN58b and RSM932A Enhances the Antitumor Response to Cisplatin in Lung Tumor Cells
por: Lacal, Juan Carlos, et al.
Publicado: (2022)

Gastrointestinal complications after fast-track total hip and knee replacement: an observational study in a consecutive 36,932 patient cohort
por: Daugberg, Louise O. H., et al.
Publicado: (2023)

Cardiovascular and Metabolic Profile of Subjects with Acne in a Cohort of Middle-aged Patients: A General Population Study of 1,932 Subjects
por: SINIKUMPU, Suvi-Päivikki, et al.
Publicado: (2023)

Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2019)

Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs
por: Hübel, Kai, et al.
Publicado: (2018)

Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil™) and granulocyte-colony stimulating factor
por: Avramova, Boryana E, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_nof5buuj792utkv4uqchn6jqtv